AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02066090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Description: manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today
Study NCT02066090 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)
Study NCT01832168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Laparoscopic Prostatectomy
Description: Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
Study NCT01832168 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic Assisted Laparoscopic Prostatectomy
Description: Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
Study NCT01734928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
Study NCT01734928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
Study NCT01734928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
Study NCT01734928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
Study NCT01734928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
Study NCT04597333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Dinoprostone vaginal insert.
Study NCT01857947 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: AECOPD Mr proADM
Study NCT01066858 — intervention group
Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
Study NCT03129685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HALED
Description: This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
Study NCT01016782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0444
Description: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Study NCT01016782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0444
Description: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Study NCT01016782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0444
Description: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Study NCT03056287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
Study NCT03056287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
Study NCT03056287 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
Study NCT04597333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical ripening balloon.
Description: Double lumen cervical ripening balloon.
Study NCT02340676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis (ECP)
Description: Participants receive ECP treatment twice a week for 16 weeks
Study NCT02340676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
Study NCT02129140 — intervention group
Intervention type: DEVICE
Intervention: Hernia graft/mesh
Description: observational group
Study NCT01832168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Application of Absorbable Hemostat
Description: Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
Study NCT01832168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of dehydrated human amniotic membrane
Description: Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
Study NCT02209909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin continuation
Description: Patients are randomized to continue aspirin before OPCAB surgery.
Study NCT02209909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin discontinuation
Description: Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
Study NCT04204642 — intervention group
Intervention type: OTHER
Intervention: CAA patients data collection
Description: Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
Study NCT02850133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: aerobic exercise training for 36 sessions within 12-16 weeks
Study NCT01214148 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ORSIRO - Drug Eluting Coronary Stent
Description: The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
Study NCT00510952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Protamine Suspension
Description: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
Study NCT00510952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
Study NCT01728038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
Study NCT03390036 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Hyaluronic Acid with Triamcinolone Hexacetonide
Study NCT03390036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc
Description: Hyaluronic Acid
Study NCT03036800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda
Description: standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
Study NCT03036800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialist Obesity Management Services
Description: Specialist Obesity Management Services standard of care
Study NCT03390036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: Triamcinolone Hexacetonide
Study NCT03036800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialist Obesity Management Services
Description: Specialist Obesity Management Services standard of care
Study NCT02142985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9% Intravenous
Description: vascular filling with 500 ml of crystalloid solution (sodium chloride 0.9%) over 30 minutes
Study NCT04615741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Yoga
Description: One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
Study NCT04615741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Psychotherapy
Description: Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
Study NCT02421003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heart surgery
Study NCT01048489 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education in the high school
Description: (12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco.
Study NCT02392832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fourstar® granule, 90 day and 180 day briquettes Bti/Bs
Description: In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs.
Study NCT03513523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 1 NRPT
Description: Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
Study NCT03513523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 2 NRPT
Description: Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
Study NCT02831868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAVAI
Description: implantation of the HAVAI device to correct the IMA angle
Study NCT02312986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
Study NCT02447107 — intervention group
Intervention type: OTHER
Intervention: Electronic Diary
Description: The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
Study NCT02447107 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
Study NCT03513523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group 3 Placebo
Description: Four placebo capsules will be taken once daily in the morning for 26 weeks.
Study NCT01681368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant (TL32711)
Description: 47mg/m\^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
Study NCT03464214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neck Muscle Vibration
Description: Local vibration device applied on neck muscles for 8 weeks
Study NCT03464214 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Stabilization Exercises
Description: Cervical stabilization exercises performed by healty individuals for 8 weeks
Study NCT01466777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional surgery type
Description: Traditional laparoscopic surgery for endometrial cancer
Study NCT01466777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic surgery
Description: Robotic assisted laparoscopic surgery for endometrial cancer
Study NCT03125291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridges 4-week Program
Description: Participants receive 4, 2-hour sessions over a 6-week period.
Study NCT01902719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) Intervention
Description: Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
Study NCT04527250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: ASC41,1mg/table;5mg/table
Study NCT01445626 — intervention group
Intervention type: DRUG
Intervention: dexamethasone intravitreal implant 0.7 mg
Description: Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
Study NCT00554983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant birch pollen allergen
Description: subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
Study NCT00554983 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
Study NCT01490515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-invasive metabolomic profiling
Description: non-invasive metabolomic profiling of IVF human embryos
Study NCT01490515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: morphological evaluation
Description: Simple microscopic observation of embryos and evaluation of morphological characteristics
Study NCT04082182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell immunotherapy
Description: Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
Study NCT04082182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific DTH
Description: Intradermal injection of 1 x 10E6 MIDRIX4-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
Study NCT04082182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Control DTH
Description: Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
Study NCT00650221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Single-dose 80 mg immediate-release oral tablet
Study NCT00650221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Single-dose 80 mg immediate-release tablet
Study NCT02703961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: concurrent chemotherapy with cisplatin
Description: in experimental group: cisplatin 60mg/m2, d1,d22;
Study NCT02703961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy with cisplatin
Description: in experimental group: cisplatin 60mg/m2, d1,d22;
Study NCT02703961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy with docetaxel
Description: in experimental group: docetaxel 60mg/m2, d1,d22;
Study NCT02703961 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: pelvic radiotherapy
Description: external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
Study NCT04527250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC41 placebo
Description: ASC41 placebo,1mg/table;5mg/table
Study NCT03060577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.